The Role of suPAR in Doxorubicin Induced Cardiomyopathy in Breast Cancer Patients
This is a pilot study examining suPAR, a biomarker closely involved with both the immune and inflammatory systems in the body. The study will look at suPAR levels in patients with breast cancer planning to receive doxorubicin (Adriamycin) chemotherapy. Eligible patients will have their blood drawn with corresponding echocardiograms to investigate whether elevated suPAR levels pre-chemotherapy may predict the onset of doxorubicin-induced cardiotoxicity. It will also examine whether elevated suPAR levels post-chemotherapy may correlate with the development of doxorubicin-induced cardiotoxicity. This study is only being conducted at Rush University Medical Center. Fifty patients are expected to enroll within two years.
In order to participate you must meet the following criteria:
- Are between 18 and 64 years of age.
- Have newly diagnosed breast cancer that has not metastasized (spread to other parts of the body).
- Plan to start treatment for breast cancer with doxorubicin chemotherapy.
You will be excluded from the study if any of the following criteria apply to you:
- Have a previous history of heart failure or reduced ejection fraction (<50%).
This is a partial list of inclusion and exclusion criteria.